metaPreg - Interferon beta 1b (IFN-beta1b) during pregnancy

Interferon beta 1b (IFN-beta1b)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.71 [0.37, 7.96]	0%	2 studies	5,001	21	not evaluable	ROB	-
Major congenital malformations	1.88 [0.33, 10.69]	0%	2 studies	4,998	21	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.32 [0.31, 5.56]	61%	3 studies	206	68	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preeclampsia	7.58 [1.10, 52.23]	-	1 study	5	10	not evaluable	ROB	14.65 [1.43; .]
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	1.70 [0.43, 6.67]	57%	2 studies	64	70	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
6 non statistically significant endpoints reported in only one study